Skip to main content
. 2023 Sep 8;2023(9):CD001888. doi: 10.1002/14651858.CD001888.pub5

3. Overview of included studies (PICO) ‐ Cancer.

Study details Surgery type CS detail Intervention detail Control detail Outcomes reported (time point)
Galaal 2019 (TIC TOC)
RCT 
Registration: Prospective 
Country: UK 
N = 55 Gynaecology (Ovarian cancer) Timing of collection: intraoperative 
Washing: washed 
Transfusion threshold: No threshold 
System: Varied according to centre Intraoperative Cell Salvage (ICS)
N = 26 Standard Treatment (Donor blood transfusion)
N = 29

  • Mortality (NR)

  • Infection (NR)
Jacobi 1997
RCT 
Registration: N/A
Country: Germany 
N = 24 Urology (Prostate cancer) Timing of collection: intraoperative 
Washing: washed 
Transfusion threshold: No protocol 
System: Cell Saver® 3 plus from Haemonetics®, Munich Group 1: autologous transfusion (Retransfusion group)
N = 12 Group 2: control (Homologous blood)
N = 12

  • Volume (NA)

  • Blood loss (NR)

  • Mortality (in‐hospital)

  • DVT (postoperative)

  • Hospital LOS (NA)

ANH: acute normovolemic haemodilution; AT: autotransfusion; CABG: cardiopulmonary bypass graft; CS: cell salvage; CVA: cerebrovascular accident; DVT: deep vein thrombosis; Hb: haemoglobin; Hct: haematocrit; LOS: hospital length of stay; MACE: major adverse cardiovascular events; MI: myocardial infarction; N: planned recruitment (as reported by the study); NA: not analysable; NR: not reported; PE: pulmonary embolism; PJI: prosthetic joint infection; RAP: retrograde autologous prime; RCT: randomised controlled trial; VTE: venous thromboembolism

"Registration: N/A" means 'not applicable' as the study was published before 2010
"Volume" refers to mean transfusion volume
"Transfusions" refers to number of people receiving an allogeneic transfusion